…GlaxoSmithKline has unveiled a combination vaccine for use in Africa that the company says will never make money...Globorix is…a meningitis A and C vaccine, but…will protect against…other diseases...Médecins sans Frontières [MSF]...welcomes the announcement...[but] “important questions about Globorix remain unanswered, such as the likely price of the vaccine”...says Tido von Schoen Angerer, executive director of MSF’s Access to Medicines programme...MSF fears that...there are likely to be shortages of the traditional…meningitis vaccine as GSK have stopped making it…Is this the new way forward for meeting the health needs of the developing world?...Or is this a pharmaceutical industry ploy designed to create markets for their products? [also refers to Serum Institute of India]